Jia-Yang Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jia-Yang Cai has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Zhi-Ming Shao
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publications - A Yong Cao
Key Laboratory of Breast Cancer in Shanghai Department of Breast Surgery Fudan University Shanghai Cancer Center Shanghai China
1 shared publication - Caijin Lin
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
1 shared publication - Da-Qiang Li
Shanghai Cancer Center and Institutes of Biomedical Sciences Shanghai Medical College Fudan University Shanghai 200032 China
1 shared publication Fang-Lin Zhang
Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China
1 shared publication- Fang-Lin Zhang
Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4) , 101
HDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4
Purpose Triple-negative breast cancer (TNBC) displays an aggressive clinicopathological profile. Despite cytotoxic chemotherapy being the primary systemic therapy, complete responses are achieved in fewer than 30% of patients, highlighting the need for new therapeutic targets and a deeper understanding of disease-driving mechanisms. Methods This study identified key oncogenic factors in TNBC through multi-omics differential analyses. Cell proliferation, migration, and invasion abilities were assessed using CCK-8, colony formation, and transwell migration and invasion assays. Quantitative proteomics was applied to profile downstream protein alterations following HDHD5 knockdown. Western blotting and RT-qPCR were used to examine expression levels in different samples. Xenograft tumor model was employed to investigate the in vivo functions of HDHD5. Results HDHD5 was highly expressed in TNBC and its elevated expression was associated with poor patient prognosis. Functional studies demonstrated that HDHD5 promotes TNBC cell proliferation and colony formation, as well as enhances cell migration and invasion. Mechanistically, HDHD5 facilitates epithelial–mesenchymal transition (EMT) associated phenotypes and promotes migratory and invasive capacities in TNBC cell lines, at least in part, through regulation of S100A4. Consistently, HDHD5 promoted TNBC tumor growth both in vitro and in vivo via S100A4. Conclusion Our study reveals HDHD5 as a previously unrecognized driver of tumor progression in TNBC and highlights its potential as a therapeutic target and prognostic biomarker for this aggressive breast cancer subtype.
- 29 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4) , 101
Open AccessHDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4
Purpose Triple-negative breast cancer (TNBC) displays an aggressive clinicopathological profile. Despite cytotoxic chemotherapy being the primary systemic therapy, complete responses are achieved in fewer than 30% of patients, highlighting the need for new therapeutic targets and a deeper understanding of disease-driving mechanisms. Methods This study identified key oncogenic factors in TNBC through multi-omics differential analyses. Cell proliferation, migration, and invasion abilities were assessed using CCK-8, colony formation, and transwell migration and invasion assays. Quantitative proteomics was applied to profile downstream protein alterations following HDHD5 knockdown. Western blotting and RT-qPCR were used to examine expression levels in different samples. Xenograft tumor model was employed to investigate the in vivo functions of HDHD5. Results HDHD5 was highly expressed in TNBC and its elevated expression was associated with poor patient prognosis. Functional studies demonstrated that HDHD5 promotes TNBC cell proliferation and colony formation, as well as enhances cell migration and invasion. Mechanistically, HDHD5 facilitates epithelial–mesenchymal transition (EMT) associated phenotypes and promotes migratory and invasive capacities in TNBC cell lines, at least in part, through regulation of S100A4. Consistently, HDHD5 promoted TNBC tumor growth both in vitro and in vivo via S100A4. Conclusion Our study reveals HDHD5 as a previously unrecognized driver of tumor progression in TNBC and highlights its potential as a therapeutic target and prognostic biomarker for this aggressive breast cancer subtype.
- Open Access
- 15 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (12)
Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer
Hormone receptor–positive and human epidermal growth factor receptor 2–negative breast cancer (HR + /HER2 − BC) is the most common subtype, with a high risk of long-term recurrence and metastasis. Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors is a standard treatment for advanced/metastatic HR + /HER2 – BC, but resistance remains a major clinical challenge. We report that kinesin family member C2 ( KIFC2 ) was amplified in approximately 50% of patients with HR + /HER2 – BC, and its high expression was associated with poor disease outcome, increased tumor protein p53 ( TP53 ) somatic mutation, and active pyrimidine metabolism. Functional assays revealed that depletion of KIFC2 suppressed growth and enhanced sensitivity of HR + /HER2 – BC cells to tamoxifen and CDK4/6 inhibitors. Mechanistically, KIFC2 stabilized CDK4 by enhancing its interaction with ubiquitin-specific peptidase 9 X-linked (USP9X). Importantly, reexpression of CDK4 in KIFC2-depleted cells partially rescued the decreased growth and increased sensitivity to tamoxifen and CDK4/6 inhibitors caused by KIFC2 depletion. Clinically, high KIFC2 mRNA expression was negatively associated with the survival rate of patients with HR + /HER2 – BC who received adjuvant ET alone or in combination with CDK4/6 inhibitors. Collectively, these findings identify an important role for KIFC2 in HR + /HER2 – BC growth and therapeutic resistance, and support its potential as a therapeutic target and predictive biomarker.
- 15 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (12)
Open AccessKinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer
Hormone receptor–positive and human epidermal growth factor receptor 2–negative breast cancer (HR + /HER2 − BC) is the most common subtype, with a high risk of long-term recurrence and metastasis. Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors is a standard treatment for advanced/metastatic HR + /HER2 – BC, but resistance remains a major clinical challenge. We report that kinesin family member C2 ( KIFC2 ) was amplified in approximately 50% of patients with HR + /HER2 – BC, and its high expression was associated with poor disease outcome, increased tumor protein p53 ( TP53 ) somatic mutation, and active pyrimidine metabolism. Functional assays revealed that depletion of KIFC2 suppressed growth and enhanced sensitivity of HR + /HER2 – BC cells to tamoxifen and CDK4/6 inhibitors. Mechanistically, KIFC2 stabilized CDK4 by enhancing its interaction with ubiquitin-specific peptidase 9 X-linked (USP9X). Importantly, reexpression of CDK4 in KIFC2-depleted cells partially rescued the decreased growth and increased sensitivity to tamoxifen and CDK4/6 inhibitors caused by KIFC2 depletion. Clinically, high KIFC2 mRNA expression was negatively associated with the survival rate of patients with HR + /HER2 – BC who received adjuvant ET alone or in combination with CDK4/6 inhibitors. Collectively, these findings identify an important role for KIFC2 in HR + /HER2 – BC growth and therapeutic resistance, and support its potential as a therapeutic target and predictive biomarker.
- Open Access
- 10 March 2022
- Published by Elsevier in Translational Oncology
- Vol. 19, 101391
TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway
- 10 March 2022
- Published by Elsevier in Translational Oncology
- Vol. 19, 101391
Open AccessTMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway